No Data
ST Tiansheng: Report for the third quarter of 2024
Tiansheng Pharmaceutical's Isoniazid Tablets Pass Chinese Drug Regulator's Consistency Evaluation
Tiansheng Pharmaceuticals Group (002872.SZ): Isoniazid tablets pass generic drug consistency evaluation.
Gelonghui, October 14th | tiansheng pharmaceutical group (002872.SZ) announced that the company recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration. The "Isoniazid Tablets" of the company passed the evaluation of generic drug quality and efficacy consistency. Isoniazid inhibits the synthesis of the key component mycolic acid of bacterial cell walls. At therapeutic concentrations, isoniazid has a bactericidal effect on intracellular and extracellular mycobacterium tuberculosis in the growth and reproduction period. Isoniazid tablets are suitable for: (1) various types of tuberculosis sensitive to isoniazid in combination with other anti-tuberculosis drugs; (2) prevention of tuberculosis; (3) according to the country
ST Tiansheng: 2024 Semi-Annual Report
ST Tiansheng: 2024 Semi-Annual Report Summary
Tiansheng Pharmaceutical Group: 2024 Interim Performance Forecast
